SCHEMBL12846005

SCHEMBL12846005

CC(=O)NS(=O)(=O)CF

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8472169 0.87
SCHEMBL4719324 0.78
SCHEMBL27874420 0.77 KDM4E (0.30)
SCHEMBL92832 0.75 MEN1 (0.36)
SCHEMBL11979591 0.74 KDM4E (0.35)
SCHEMBL7023074 0.74
SCHEMBL724276 0.74
SCHEMBL13768228 0.73 ALDH1A1 (0.33)
SCHEMBL13963033 0.73 ALDH1A1 (0.39)
SCHEMBL7987882 0.72 HPGD (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897629-B2 Therapeutic compounds ALLERGAN, INC. (US) 2011-03-01 US disclosed
US-20100168189-A1 THERAPEUTIC SUBSTITUTED LACTAMS ALLERGAN, INC. 2010-07-01 US disclosed
US-20090247594-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-10-01 US disclosed
EP-1581523-B1 PYRAZOLE-DERIVATIVES AS FACTOR XA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-09-30 EP disclosed
US-7576112-B2 Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives ALLERGAN, INC. (US) 2009-08-18 US disclosed
US-20090016981-A1 THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2009-01-15 US disclosed
US-20080058387-A1 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts ALLERGAN, INC. 2008-03-06 US disclosed